Men's Health News

RSS

Allergic conditions that result from hyper reactive immune system may lower cancer risk: Study

If you have asthma or eczema, your hyper reactive immune system may lower your risk of some of the most common types of cancer, according to a study published this month in Annals of Allergy, Asthma & Immunology, the scientific journal of the American College of Allergy, Asthma and Immunology.

12 May 2010

Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients

Quest PharmaTech Inc., a pharmaceutical company developing and commercializing products for the treatment of cancer, today announced the dosing of the first patient under the Company's recently initiated Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients. The study will evaluate the localization, safety, tolerability and preliminary treatment response of SL052 photodynamic therapy in 18 patients with localized prostate cancer.

12 May 2010

Older Americans staying sexually active but not practicing safe sex

Sexual activity continues to thrive with the 45+ demographic according to a new AARP sex survey, Sex, Romance, and Relationships: AARP Survey of Midlife and Older Adults, released today. However, older adults are not necessarily practicing what they preach to younger generations, with results showing a low use of protection among sexually active dating singles with only one in five reporting use of condoms regularly.

11 May 2010

UNC-CH awarded $100,000 Grand Challenges Explorations grant for study of ultrasound as a contraceptive

The University of North Carolina at Chapel Hill has received a $100,000 Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation. The grant will support an innovative global health research project conducted by James Tsuruta, PhD, and Paul Dayton, PhD, titled "Ultrasound as a long-term, reversible contraceptive."

11 May 2010

Medical options to help prostate cancer patients make informed treatment decisions

While the dreaded words "You have prostate cancer" often leave patients confused, the impact of the diagnosis can extend to the entire family, especially wives, says a top expert.

10 May 2010

Experts to present latest research on prostate cancer and related conditions

WHAT: This symposium features a renowned faculty of clinicians and researchers who will present leading-edge information on the best standards of care in managing the full spectrum of prostate cancer and related conditions.

10 May 2010

Preoperative MRI helps spare erectile function, continence after RALP for prostate cancer

Preoperative prostate magnetic resonance imaging (MRI) can help urologic surgeons spare the neurovascular bundle (NVB) (which controls a man's erectile function and continence) during a robotic assisted laparoscopic prostatectomy (RALP) for the treatment of prostate cancer, according to a study to be presented at the ARRS 2010 Annual Meeting in San Diego, CA.

7 May 2010

Australia’s first ever health policy for men

Prime Minister Kevin Rudd yesterday announced Australia’s first ever men’s health policy called the “National Male Health Policy”. He said in the announcement during a visit to the Whittlesea Men's Shed in Victoria, “They either think that they're invincible that they can just tough it out…'They don't like talking about it usually, and frankly, the problem with all that is it makes it really hard to deal with men's health problems before they become too serious.” He felt this move was long due. He added, “'It's a pretty important time that we do that, we're probably about 110 years late.”

6 May 2010

FDA approves Provenge for treating men with advanced prostate cancer

The US Food and Drug Administration has approved a new 'cancer vaccine' for treating men with advanced prostate cancer.

6 May 2010

Nymox Pharmaceutical announces new positive results from long term outcome study of NX-1207 for BPH

Nymox Pharmaceutical Corporation today announced new 2010 positive results from a long term outcome study of NX-1207 for benign prostatic hyperplasia (BPH). The study evaluated symptomatic progress of U.S. patients involved in the Company's NX02-0012 and NX02-0013 Phase 1-2 studies of NX-1207 initially undertaken in 2003. Patients treated with NX-1207 were followed-up on an unselected and as available basis and assessed for symptomatic improvement, treatment outcomes, and durability of efficacy 6 ½ years after a single treatment with NX-1207.

5 May 2010

LA BioMed receives $1.5M in grant to study contraceptive for men

As the birth control pill marks its 50th birthday this month, Los Angeles Biomedical Research Institute announced today that it has received $1.5 million in grant funding to study a contraceptive for men that uses a combination of two hormonal gels applied to the skin of the arm and abdomen.

4 May 2010

Obese men more likely to have low testosterone than non-obese men: HIM study

Obesity, a condition linked to heart disease and diabetes, now appears to be associated with another health problem, but one that affects men only -- low testosterone levels.

4 May 2010

FDA issues advisory on prostate cancer drugs

Gonadotropin-Releasing Hormone (GnRH) agonists, a class of medications primarily used to treat men with prostate cancer, have been associated with a small increased risk for diabetes, heart attack, stroke, and sudden death in men treated with one of the medications, according to a preliminary and ongoing analysis of several studies by the U.S. Food and Drug Administration.

3 May 2010

BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development

BioSante Pharmaceuticals, Inc. today announced that development of its GVAX Prostate Cancer Vaccine (GVAX Prostate) for the treatment of prostate cancer has been reinitiated. Manufacturing of new GVAX Prostate is in process, regulatory steps to lift the GVAX Prostate clinical hold prior to trial initiation are being taken, and prostate cancer patients are expected to be treated in a Phase II human clinical trial beginning in the fourth quarter of 2010 at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.

3 May 2010

Advaxis advances lead prostate cancer immunotherapeutic toward clinical trials

Advaxis, the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, is advancing the clinical development of its lead prostate cancer immunotherapeutic toward clinical trials.

3 May 2010

FDA oks 'vaccine' to treat prostate cancer

Provenge, developed by Dendreon Corporation, is the first approved "treatment that uses a so-called cancer vaccine, a drug that trains the body's own immune system to fight the disease," The New York Times reports.

3 May 2010

Approval of Provenge marks beginning of new era in cancer treatment: Dana-Farber Cancer Institute

Today's announcement that the U.S. Food and Drug Administration has approved Provengeâ, a new form of therapy for some prostate cancer patients, marks the beginning of an era in which patients' own immune systems become part of the standard therapeutic arsenal against cancer, say Dana-Farber Cancer Institute investigators who led a study of the treatment's effectiveness in patients.

30 Apr 2010

PROVENGE receives FDA approval for treatment of CRPC

Dendreon Corporation today announced that the U.S. Food and Drug Administration has approved PROVENGE (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer.

30 Apr 2010

FDA approves new treatment option for prostate cancer

Today is an exciting day for men with advanced prostate cancer and the millions of families and loved ones who are profoundly affected. Today a new prostate cancer treatment option, Provenge, was approved by the Food and Drug Administration.

30 Apr 2010

Provenge cellular immunotherapy for men with advanced prostate cancer receives FDA approval

The U.S. Food and Drug Administration today approved Provenge (sipuleucel-T), a new therapy for certain men with advanced prostate cancer that uses their own immune system to fight the disease.

30 Apr 2010

Men's Health News

Allergic conditions that result from hyper reactive immune system may lower cancer risk: Study

Quest initiates dosing in Phase I clinical trial with SL052 Photodynamic Therapy in prostate cancer patients

Older Americans staying sexually active but not practicing safe sex

UNC-CH awarded $100,000 Grand Challenges Explorations grant for study of ultrasound as a contraceptive

Medical options to help prostate cancer patients make informed treatment decisions

Experts to present latest research on prostate cancer and related conditions

Preoperative MRI helps spare erectile function, continence after RALP for prostate cancer

Australia’s first ever health policy for men

FDA approves Provenge for treating men with advanced prostate cancer

Nymox Pharmaceutical announces new positive results from long term outcome study of NX-1207 for BPH

LA BioMed receives $1.5M in grant to study contraceptive for men

Obese men more likely to have low testosterone than non-obese men: HIM study

FDA issues advisory on prostate cancer drugs

BioSante Pharmaceuticals reinitiates GVAX Prostate Cancer Vaccine development

Advaxis advances lead prostate cancer immunotherapeutic toward clinical trials

FDA oks 'vaccine' to treat prostate cancer

Approval of Provenge marks beginning of new era in cancer treatment: Dana-Farber Cancer Institute

PROVENGE receives FDA approval for treatment of CRPC

FDA approves new treatment option for prostate cancer

Provenge cellular immunotherapy for men with advanced prostate cancer receives FDA approval

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News